Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BCHE | P06276 | 4/20 | 0.48 |
| ▸ | CHRM2 | P08172 | 2/20 | 0.43 |
| ▸ | CHRM4 | P08173 | 2/20 | 0.43 |
| ▸ | CHRM1 | P11229 | 2/20 | 0.43 |
| ▸ | CHRM3 | P20309 | 2/20 | 0.43 |
| ▸ | MEN1 | O00255 | 1/20 | 0.42 |
| ▸ | MAPT | P10636 | 1/20 | 0.42 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.42 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.42 |
| ▸ | CHRNA7 | P36544 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9618911 | 1.00 | BCHE (0.48) | BCHECHRM2CHRM4CHRM1CHRM3 | |
| SCHEMBL23710673 | 0.84 | MEN1 (0.42) | BCHEMEN1MAPTKMT2AHSD17B10 | |
| SCHEMBL18202479 | 0.84 | MEN1 (0.42) | BCHEMEN1MAPTKMT2AHSD17B10 | |
| SCHEMBL24772411 | 0.84 | MEN1 (0.42) | BCHEMEN1MAPTKMT2AHSD17B10 | |
| SCHEMBL16140946 | 0.83 | BCHE (0.50) | BCHECHRM2CHRM4CHRM1CHRM3 | |
| SCHEMBL18288604 | 0.83 | TRPM8 (0.45) | BCHEMEN1MAPTKMT2AHSD17B10 | |
| SCHEMBL20067804 | 0.83 | BCHE (0.40) | BCHECHRM2CHRM4CHRM1CHRM3 | |
| SCHEMBL16140945 | 0.76 | BCHE (0.41) | BCHECHRM2CHRM4CHRM1CHRM3 | |
| SCHEMBL1751897 | 0.76 | LMNA (0.48) | MEN1MAPTKMT2AHSD17B10CHRNA7 | |
| SCHEMBL636837 | 0.76 | LMNA (0.48) | MEN1MAPTKMT2AHSD17B10CHRNA7 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230159929-A1 | MODIFIED SHORT INTERFERING NUCLEIC ACID (siNA) MOLECULES AND USES THEREOF | ALIGOS THERAPEUTICS, INC. | 2023-05-25 | — | — | US | disclosed |
| US-20160355805-A1 | Double Stranded Oligonucleotide Compounds Comprising Positional Modifications | QUARK PHARMACEUTICALS, INC. | 2016-12-08 | — | — | US | disclosed |
| EP-2649181-B1 | DOUBLE STRANDED OLIGONUCLEOTIDE COMPOUNDS COMPRISING POSITIONAL MODIFICATIONS | QUARK PHARMACEUTICALS INC (US) | 2016-04-27 | — | — | EP | disclosed |
| WO-2012078536-A2 | DOUBLE STRANDED OLIGONUCLEOTIDE COMPOUNDS COMPRISING POSITIONAL MODIFICATIONS | QUARK PHARMACEUTICALS, INC. (US) | 2012-06-14 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230159929-A1 | MODIFIED SHORT INTERFERING NUCLEIC ACID (siNA) MOLECULES AND USES THEREOF | SNRPA, SNRPA1, NSUN2 | BCHE 4825/4885CHRM2 4884/4885CHRM4 4881/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.